Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
159M
-
Number of holders
-
140
-
Total 13F shares, excl. options
-
63.8M
-
Shares change
-
+6.57M
-
Total reported value, excl. options
-
$628M
-
Value change
-
+$63.3M
-
Put/Call ratio
-
0.16
-
Number of buys
-
73
-
Number of sells
-
-64
-
Price
-
$9.84
Significant Holders of TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) as of Q1 2020
181 filings reported holding TGTX - TG THERAPEUTICS, INC. - COMMON STOCK as of Q1 2020.
TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) has 140 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 63.8M shares
of 159M outstanding shares and own 40.17% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (10.4M shares), FMR LLC (9.52M shares), BlackRock Inc. (6.1M shares), VANGUARD GROUP INC (4.45M shares), STATE STREET CORP (3.49M shares), GREAT POINT PARTNERS LLC (2.56M shares), Eversept Partners, LP (2.46M shares), CITADEL ADVISORS LLC (2.18M shares), ALKEON CAPITAL MANAGEMENT LLC (1.57M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.34M shares).
This table shows the top 140 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.